Which of the following statements are true about Iprivask?
A. It is a direct thrombin inhibitor
B. It is administered IM
C. It requires dose adjustment in renal impairment
D. Plt count needs to be monitored during tx
E. aPTT needs to be monitored in pts with increased risk of bleeding
